You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 105 No. 7, July 1987 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  LABORATORY SCIENCES
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (24)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Potential of Topical Norfloxacin Therapy

Comparative In Vitro Activity Against Clinical Ocular Bacterial Isolates

Ellie J. G. Goldstein, MD; Diane M. Citron; Lauren Bendon; Alice E. Vagvolgyi; Melvin D. Trousdale, PhD; Maria D. Appleman, PhD

Arch Ophthalmol. 1987;105(7):991-994.


Abstract



• Norfloxacin, a new fluoroquinolone antibiotic related to nalidixic acid, was evaluated as a topical agent for clinical efficacy in bacterial eye infections. This study reports on the comparative in vitro activity of norfloxacin and ten topical antibiotics (nalidixic acid, polymyxin B, colistin, bacitracin, chloramphenicol, sulfamethoxazole, tetracycline, erythromycin, gentamicin, and tobramycin) against 203 pathogenic eye isolates of 17 genera (37 species). In general, norfloxacin had the greatest potency and broadest spectrum of activity of the agents tested. It was active against Staphylococcus aureus (minimal inhibitory concentration against 90% [MIC90], ≤ 1.0 µg/mL), coagulase-negative staphylococci (MIC90, ≤1.0 µg/mL), Pseudomonas aeruginosa (MIC90, ≤1.0 µg/mL), and Haemophilus organisms (MIC90, ≤1.0 µg/mL).



Author Affiliations



From the R. M. Alden Research Laboratory, Santa Monica (Calif) Hospital Medical Center (Dr Goldstein and Mss Citron, Bendon, and Vagvolgyi); the Departments of Ophthalmology and Microbiology, Estelle Doheny Eye Foundation and Hospital (Dr Trousdale); and Los Angeles County-University of Southern California Medical Center (Dr Appleman), Los Angeles.


Footnotes



Accepted for publication March 12, 1987.

Reprint requests to R. M. Alden Research Laboratory, 11980 San Vicente Blvd, No. 103, Los Angeles, CA 90049 (Dr Goldstein).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Bactericidal effect of intravitreal levofloxacin in an experimental model of endophthalmitis
Ferrer et al.
Br J Ophthalmol 2008;92:678-682.
ABSTRACT | FULL TEXT  

Current approach to postoperative endophthalmitis
SUNARIC-MEGEVAND and POURNARAS
Br J Ophthalmol 1997;81:1006-1015.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1987 American Medical Association. All Rights Reserved.